Reprieve Cardiovascular
Reprieve Cardiovascular raises $61M Series B at $300M valuation
Quick Facts
Reprieve Cardiovascular: Series B Funding Round
Reprieve Cardiovascular has successfully raised $61M in Series B funding, reaching a valuation of $300M.
Company Overview
Developer of therapy for acute decompensated heart failure
Funding Details
The Series B round was led by New Enterprise Associates, with participation from Sofinnova Partners.
Company Information
- Headquarters: Milford, MA
- Founded: 2018
- Employees: 70+
- Category: HealthTech
Investment
Reprieve Cardiovascular plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series B
- Sofinnova Partners: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Zingage raises $12.5M Seed at $60M valuation
Zingage raises $12.5M in Seed at $60M valuation. AI platform for home healthcare coordination and patient engagement...
AccelerateStack Platform raises $75M Series C at $226M valuation
AccelerateStack Platform secures $75M in Series C funding led by Intel Capital, reaching $226M valuation as it accelerates growth in the healthtech sector.
Duos raises $130M Growth Equity at $600M valuation
Duos raises $130M in Growth Equity at $600M valuation. Digital health platform for Medicare-focused patient care...